Tizanidine Hydrochloride Capsule
Product Images NDC 71209-064

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 71209-064). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cadila Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tizanidine-spl-container-label-2mg-150cap (Tizanidine Spl Container Label 2mg 150cap)

Label for Tizanidine Hydrochloride capsules, 2 mg strength, manufactured by Cadila Pharmaceuticals Limited in Gujarat, India. The label indicates 150 capsules per container, with storage instructions and a caution to keep out of reach of children. It includes a barcode, the Rx only designation, and notes that the product is not interchangeable with tizanidine tablets or Zanaflex tablets.*

FDA Label Image

Tizanidine-spl-container-label-4mg-150cap (Tizanidine Spl Container Label 4mg 150cap)

Label for Tizanidine Hydrochloride Capsules, 4 mg strength, oral capsules, with a package count of 150 capsules. The label includes storage instructions, a warning to keep out of reach of children, and a note that the capsules contain 4.58 mg tizanidine hydrochloride equivalent to 4 mg tizanidine base. Manufactured by Cadila Pharmaceuticals Limited.*

FDA Label Image

Tizanidine-spl-container-label-6mg-150cap (Tizanidine Spl Container Label 6mg 150cap)

Label for Tizanidine Hydrochloride Capsules, 6 mg strength, oral dosage form. The label indicates 150 capsules per container. It includes storage instructions, a caution to keep medication out of reach of children, and a note that the product is manufactured by Cadila Pharmaceuticals Limited, Gujarat, India. There is also a warning that these capsules are not interchangeable with tizanidine or Zanaflex tablets.*

FDA Label Image

Fig1 (Tizanidine Spl Fig 1)

A line graph depicting plasma tizanidine concentration (ng/mL) over 24 hours post-dosing. It compares four conditions: 2 x 4 mg tizanidine tablets with and without food, and 2 x 4 mg tizanidine capsules with and without food. The x-axis represents hours from dosing, and the y-axis shows plasma concentration levels.*

FDA Label Image

Fig2 (Tizanidine Spl Fig 2)

A line graph depicting improvement in Ashworth Score over 6 hours post-dose for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis shows improvement scores, and the x-axis shows hours after dosing. Error bars indicate variability at each time point.*

FDA Label Image

Fig3 (Tizanidine Spl Fig 3)

A line and bar chart displaying improvement in Ashworth Score over time comparing Tizanidine (mean dose 28.8 mg) to placebo. The X-axis shows study time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). The Y-axis shows improvement scores, with Tizanidine consistently showing greater improvement than placebo at all time points.*

FDA Label Image

Structure (Tizanidine Spl Structure)

Chemical structure of tizanidine hydrochloride, showing its molecular framework with a chlorinated benzene ring fused to an imidazoline moiety, along with the hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.